anonymous
Guest
anonymous
Guest
Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients Following Independent, Unblinded Interim Analysis | Athira Pharma
https://investors.athira.com/news-r...rma-advances-phase-23-lift-ad-clinical-study/
https://investors.athira.com/news-r...rma-advances-phase-23-lift-ad-clinical-study/